CA3232972A1 - Endoxifen for treatment of cancers - Google Patents
Endoxifen for treatment of cancers Download PDFInfo
- Publication number
- CA3232972A1 CA3232972A1 CA3232972A CA3232972A CA3232972A1 CA 3232972 A1 CA3232972 A1 CA 3232972A1 CA 3232972 A CA3232972 A CA 3232972A CA 3232972 A CA3232972 A CA 3232972A CA 3232972 A1 CA3232972 A1 CA 3232972A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- endoxifen
- response
- subject
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163272869P | 2021-10-28 | 2021-10-28 | |
| US63/272,869 | 2021-10-28 | ||
| PCT/US2022/048061 WO2023076496A1 (en) | 2021-10-28 | 2022-10-27 | Endoxifen for treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3232972A1 true CA3232972A1 (en) | 2023-05-04 |
Family
ID=86158538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3232972A Pending CA3232972A1 (en) | 2021-10-28 | 2022-10-27 | Endoxifen for treatment of cancers |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041245A1 (enExample) |
| EP (1) | EP4422608A4 (enExample) |
| JP (1) | JP2024541900A (enExample) |
| KR (1) | KR20240093500A (enExample) |
| CN (1) | CN118159259A (enExample) |
| AU (1) | AU2022378576A1 (enExample) |
| CA (1) | CA3232972A1 (enExample) |
| IL (1) | IL312037A (enExample) |
| MX (1) | MX2024005220A (enExample) |
| WO (1) | WO2023076496A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022232924A1 (en) * | 2021-03-11 | 2023-07-06 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
| CN117338780A (zh) * | 2023-09-21 | 2024-01-05 | 中国人民解放军海军军医大学 | 帕罗西汀在制备抗肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033430A1 (en) * | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
| EP2773340B1 (en) * | 2011-11-04 | 2020-01-08 | Myron R. Szewczuk | Use of neu1 sialidase inhibitors in the treatment of cancer |
| DE102015222031A1 (de) * | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
| WO2017127442A1 (en) * | 2016-01-18 | 2017-07-27 | The Regents Of The University Of California | Methods for treating cancer with rorgamma inhibitors |
| JP7662204B2 (ja) * | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| CN115087466A (zh) * | 2019-12-12 | 2022-09-20 | 森迪生物科学公司 | 用于细胞的调控装甲的方法和组合物 |
| AU2022232924A1 (en) * | 2021-03-11 | 2023-07-06 | Atossa Therapeutics, Inc. | Endoxifen for treatment of ovarian cancer |
| CN119300811A (zh) * | 2022-04-26 | 2025-01-10 | 阿托萨治疗学公司 | 高剂量因多昔芬制剂和使用方法 |
-
2022
- 2022-10-27 WO PCT/US2022/048061 patent/WO2023076496A1/en not_active Ceased
- 2022-10-27 AU AU2022378576A patent/AU2022378576A1/en active Pending
- 2022-10-27 CN CN202280071316.2A patent/CN118159259A/zh active Pending
- 2022-10-27 CA CA3232972A patent/CA3232972A1/en active Pending
- 2022-10-27 MX MX2024005220A patent/MX2024005220A/es unknown
- 2022-10-27 JP JP2024524402A patent/JP2024541900A/ja active Pending
- 2022-10-27 US US18/704,892 patent/US20250041245A1/en active Pending
- 2022-10-27 EP EP22888189.2A patent/EP4422608A4/en active Pending
- 2022-10-27 IL IL312037A patent/IL312037A/en unknown
- 2022-10-27 KR KR1020247013409A patent/KR20240093500A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023076496A1 (en) | 2023-05-04 |
| EP4422608A4 (en) | 2025-09-24 |
| US20250041245A1 (en) | 2025-02-06 |
| EP4422608A1 (en) | 2024-09-04 |
| JP2024541900A (ja) | 2024-11-13 |
| MX2024005220A (es) | 2024-05-16 |
| KR20240093500A (ko) | 2024-06-24 |
| IL312037A (en) | 2024-06-01 |
| CN118159259A (zh) | 2024-06-07 |
| AU2022378576A1 (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12281056B2 (en) | Methods for making and using endoxifen | |
| US20250041245A1 (en) | Endoxifen for treatment of cancers | |
| TW202340135A (zh) | （ｚ）—因多昔芬之組合物及其富集方法 | |
| AU2026200456A1 (en) | Treatment of canine cancers | |
| US20250235451A1 (en) | Methods of Delaying Pain Progression And Treating Prostate Cancer | |
| CA3203125A1 (en) | Endoxifen for treatment of ovarian cancer | |
| WO2024091551A1 (en) | Crystalline forms, pharmaceutical compositions and methods of use thereof | |
| HK40105626A (zh) | 用於治疗癌症的因多昔芬 | |
| WO2026101937A1 (en) | Compositions comprising (z)-endoxifen and a cdk4/6 inhibitor and methods of use thereof | |
| WO2025151443A1 (en) | Endoxifen for treatment of rare cancers | |
| HK40031003A (en) | Methods for making and using endoxifen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20240710 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241010 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241010 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260310 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260310 |